Mga Batayang Estadistika
| LEI | 549300RGE06P3ECANU72 |
| CIK | 1321732 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Penumbra, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 27, 2025 |
Penumbra, Inc. Names Shruthi Narayan as Company President Exhibit 99.1 Penumbra, Inc. Names Shruthi Narayan as Company President ALAMEDA, Calif. – August 27, 2025 – Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025. She will continue to report to Adam Elsesser, who served in the role of President prior to this promotion and will c |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 29, 2025 |
Penumbra, Inc. Reports Second Quarter 2025 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2025 Financial Results ALAMEDA, Calif., July 29, 2025 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. •Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| May 30, 2025 |
THIRD AMENDED AND RESTATED BYLAWS OF PENUMBRA, INC. Adopted May 28, 2025 * * * * * ARTICLE 1 OFFICES Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF PENUMBRA, INC. Adopted May 28, 2025 * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Dover, County of Kent, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 30, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PENUMBRA, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PENUMBRA, INC. The undersigned, Johanna Roberts, does hereby verify that: ONE: She is the duly elected and acting Executive Vice President, General Counsel and Secretary of Penumbra, Inc., a corporation organized and existing under the laws of the State of Delaware. TWO: The original Certificate of Incorporation of the Corporation wa |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| April 23, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 23, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| April 23, 2025 |
Penumbra, Inc. Reports First Quarter 2025 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2025 Financial Results ALAMEDA, Calif., April 23, 2025 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. •Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first q |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 21, 2025 |
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors Exhibit 99.1 Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's |
|
| February 18, 2025 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results ALAMEDA, Calif., Feb. 18, 2025 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: •Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the |
|
| February 18, 2025 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty Ltd Australia Penumbra Neuro Canada Inc. Canada Penumbra Latin America Distribuidora de Equipamentos e Produtos Médicos Ltda. Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore Pte. Ltd. Singapore |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 18, 2025 |
PENUMBRA, INC. Statement of Policy Concerning Trading in Company Securities Adopted August 18, 2015 As amended April 30, 2021 and February 17, 2023 I. SUMMARY OF POLICY CONCERNING TRADING IN COMPANY SECURITIES The policy of Penumbra, Inc. (the “Company”) is to comply with laws and regulations concerning trading in the Company’s securities. Due to the seriousness of the issues surrounding insider t |
|
| February 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 18, 2025 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 12, 2024 |
PEN / Penumbra, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| October 30, 2024 |
Penumbra, Inc. Reports Third Quarter 2024 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2024 Financial Results ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. •Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency1, compared to the thir |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 30, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 25, 2024 |
October 25, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christie Wong and Li Xiao Re: Penumbra, Inc. Form 10-K for the Fiscal Year ended December 31, 2023 Form 8-K filed July 30, 2024 Response Dated September 17, 2024 File No. 001-37557 Dear Christie Wong and Li Xiao: This letter is submitted on behalf of Penumbr |
|
| September 17, 2024 |
CONFIDENTIAL TREATMENT REQUESTED BY PENUMBRA, INC. FOIA CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO C.F.R. § 200.83 September 17, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christie Wong and Li Xiao Re: Penumbra, Inc. Form 10-K for the Fiscal Year ended December 31, 2023 Form 10-Q for the Fiscal Quarter ended June 30, 2024 Form 8-K filed July 30, 2024 File No. |
|
| August 13, 2024 |
Exhibit 99.1 Penumbra, Inc. Announces $200 Million Share Repurchase Authorization To Include $100 Million Accelerated Share Repurchase ALAMEDA, Calif., Aug. 13, 2024 /PRNewswire/ – Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today announced that its Board of Directors approved on August 5, 2024 a share repurchase authorization in the amount of up to $200 million, allowing |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Comm |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| July 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commis |
|
| July 30, 2024 |
Penumbra, Inc. Reports Second Quarter 2024 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2024 Financial Results ALAMEDA, Calif., July 30, 2024 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024. •Revenue of $299.4 million in the second quarter of 2024, an increase of 14.5% or 14.7% in constant currency1, com |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| May 7, 2024 |
Penumbra, Inc. Reports First Quarter 2024 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2024 Financial Results ALAMEDA, Calif., May 7, 2024 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. •Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency1, compare |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 21, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| March 21, 2024 |
March 20, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Penumbra, Inc.'s Form 8-K dated March 17, 2024, and we agree with the statements made in paragraphs 3, 4, 5 and 6 therein. Yours truly, /s/ DELOITTE & TOUCHE LLP |
|
| February 22, 2024 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results ALAMEDA, Calif., Feb. 22, 2024 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: •Revenue of $284.7 million for the fourth quarter of 2023, |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2024 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 22, 2024 |
EQUITY AWARD AGREEMENT AMENDMENT Exhibit 10.20 EQUITY AWARD AGREEMENT AMENDMENT This Equity Award Agreement Amendment (this “Amendment”) is dated as of January 4, 2023, by and between Penumbra, Inc., a Delaware corporation (the “Company”), and Maggie Yuen (“Participant”). RECITALS WHEREAS, the Company and Participant are parties to those certain equity award agreements, dated as of December 16, 2019 and November 15, 2021 and atta |
|
| February 22, 2024 |
THIRD AMENDMENT TO LEASE AGREEMENT Exhibit 10.5 THIRD AMENDMENT TO LEASE AGREEMENT This Third Amendment to Lease Agreement (this “Third Amendment”) is made and intended to be effective as of October 1, 2023 (the “Third Amendment Effective Date”), between HARBOR BAY NLA LLC, a Delaware limited liability company (together with any of its successors or assigns, hereinafter called the “Landlord”), and PENUMBRA, INC., a Delaware corpora |
|
| February 22, 2024 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty Ltd Australia Penumbra Neuro Canada Inc. Canada Penumbra Latin America Distribuidora de Equipamentos e Produtos Médicos Ltda. Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore Pte. Ltd. Singapore |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 22, 2024 |
EQUITY AWARD AGREEMENT AMENDMENT Exhibit 10.19 EQUITY AWARD AGREEMENT AMENDMENT This Equity Award Agreement Amendment (this “Amendment”) is dated as of January 4, 2023, by and between Penumbra, Inc., a Delaware corporation (the “Company”), and Johanna Roberts (“Participant”). RECITALS WHEREAS, the Company and Participant are parties to those certain equity award agreements, dated as of May 15, 2019, April 15, 2021 and November 15 |
|
| February 22, 2024 |
EQUITY AWARD AGREEMENT AMENDMENT Exhibit 10.21 EQUITY AWARD AGREEMENT AMENDMENT This Equity Award Agreement Amendment (this “Amendment”) is dated as of January 4, 2023, by and between Penumbra, Inc., a Delaware corporation (the “Company”), and Lambert Shiu (“Participant”). RECITALS WHEREAS, the Company and Participant are parties to that certain equity award agreement, dated as of November 15, 2021 and attached hereto as Exhibit |
|
| February 22, 2024 |
PENUMBRA, INC. COMPENSATION RECOUPMENT POLICY Adopted October 30, 2023 Exhibit 97.1 PENUMBRA, INC. COMPENSATION RECOUPMENT POLICY Adopted October 30, 2023 This Penumbra, Inc. Compensation Recoupment Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Penumbra, Inc. (the “Company”) on October 30, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from materi |
|
| February 13, 2024 |
PEN / Penumbra, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01682-penumbrainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Penumbra Inc Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule |
|
| February 9, 2024 |
PEN / Penumbra, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 2, 2023 |
Penumbra, Inc. Reports Third Quarter 2023 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2023 Financial Results ALAMEDA, Calif., Nov. 2, 2023 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2023. •Revenue of $270.9 million in the third quarter of 2023, an increase of 26.8% or 25.9% in constant currency1, co |
|
| August 3, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or or |
|
| August 1, 2023 |
Penumbra, Inc. Reports Second Quarter 2023 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2023 Financial Results ALAMEDA, Calif., Aug. 1, 2023 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023. •Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as reported and in constant currency |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| May 2, 2023 |
Penumbra, Inc. Reports First Quarter 2023 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2023 Financial Results ALAMEDA, Calif., May 2, 2023 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. •Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency1, compa |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 2, 2023 |
AMENDMENT NO. 3 Dated as of February 17, 2023 CREDIT AGREEMENT Dated as of April 24, 2020 Exhibit 10.1 Execution Version AMENDMENT NO. 3 Dated as of February 17, 2023 to CREDIT AGREEMENT Dated as of April 24, 2020 THIS AMENDMENT No. 3 (“Amendment”) is entered into as of February 17, 2023 by and among Penumbra, Inc. (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), under |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| February 23, 2023 |
28 Exhibit 10.28 LEASE AGREEMENT ANDERSON LOGISTICS ASSETS LLC Landlord AND PENUMBRA, INC. Tenant AT 1070 South 3800 West Salt Lake City, Utah 126390.00400/118481426v.4 04/15/2019 05:55 A4P4 LEASE AGREEMENT THIS LEASE AGREEMENT is made by and between ANDERSON LOGISTICS ASSETS LLC, a Delaware limited liability company (“Landlord”) and PENUMBRA, INC., a Delaware corporation (“Tenant”), and is dated |
|
| February 23, 2023 |
Exhibit 10.27 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of April 1, 2022 (the “Fifth Amendment Effective Date”), by and between HARBOR BAY CA LLC, a Delaware limited liability company (“Landlord”), and PENUMBRA, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor-in-interest to South Loop 1, LLC) and Tenant entered into that |
|
| February 23, 2023 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty Ltd Australia Penumbra Neuro Canada Inc. Canada Penumbra Latin America Distribuidora de Equipamentos e Produtos Médicos Ltda. Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore Pte. Ltd. Singapore |
|
| February 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Penumbra, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (2) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| February 23, 2023 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Penumbra, Inc. (“Penumbra,” the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.001 per share. The following description of our capital stock is |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2023 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 23, 2023 |
Exhibit 10.1 LEASE AGREEMENT By and Between 1321 & 1351 HARBOR BAY LLC, a Delaware limited liability company (“Landlord”) and PENUMBRA, INC., a Delaware corporation (“Tenant”) January 1, 2022 3489-00015 TABLE OF CONTENTS Page ARTICLE 1 PREMISES; COMMON AREAS 2 ARTICLE 2 TERM AND CONDITION OF PREMISES 4 ARTICLE 3 USE, NUISANCE, OR HAZARD 4 ARTICLE 4 RENT 6 ARTICLE 5 RENT ADJUSTMENT 7 ARTICLE 6 SERV |
|
| February 23, 2023 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results ALAMEDA, Calif., Feb. 23, 2023 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights: •Revenue of $221.2 million for the fourth quarter of 2022, |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 13, 2023 |
PEN / Penumbra Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 9, 2023 |
PEN / Penumbra Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01653-penumbrainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Penumbra Inc. Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| November 3, 2022 |
Penumbra, Inc. Reports Third Quarter 2022 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2022 Financial Results ALAMEDA, Calif., November 3, 2022 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2022. •Revenue of $213.7 million in the third quarter of 2022, an increase of 12.4%, or 15.1% in constant currenc |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 5, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF PENUMBRA, INC. Adopted August 1, 2022 * * * * * Article 1OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Dover, County of Kent, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Boar |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| August 5, 2022 |
Penumbra, Inc. Reports Second Quarter 2022 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2022 Financial Results ALAMEDA, Calif., August 4, 2022 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2022. ?Revenue of $208.3 million in the second quarter of 2022, an increase of 13.1%, or 15.3% in constant currency1, |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 3, 2022 |
AMENDMENT NO. 2 Dated as of February 18, 2022 CREDIT AGREEMENT Dated as of April 24, 2020 Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 2 Dated as of February 18, 2022 to CREDIT AGREEMENT Dated as of April 24, 2020 THIS AMENDMENT No. 2 (?Amendment?) is entered into as of February 18, 2022 by and among Penumbra, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?), under |
|
| May 3, 2022 |
Penumbra, Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2022 Financial Results ALAMEDA, Calif., May 3, 2022 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022. ?Revenue of $203.9 million in the first quarter of 2022, an increase of 20.5%, or 21.8% in constant currency1, compa |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 4, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commis |
|
| February 22, 2022 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty Ltd Australia Penumbra Neuro Canada Inc. Canada Penumbra Latin America Distribuidora de Equipamentos e Produtos M?dicos LTDA. Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore Pte. Ltd. Singapore |
|
| February 22, 2022 |
FIRST AMENDMENT TO LEASE AGREEMENT Exhibit 10.7 FIRST AMENDMENT TO LEASE AGREEMENT This First Amendment to Lease Agreement (this ?First Amendment?) is made and intended to be effective as of July 14, 2021 (the ?Effective Date?), between HARBOR BAY NLA LLC, a Delaware limited liability company (together with any of its successors or assigns, hereinafter called the ?Landlord?), and PENUMBRA, INC., a Delaware corporation (together wit |
|
| February 22, 2022 |
Exhibit 10.31 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Second Amendment?) is made and entered into as of August 5, 2020 (the ? Second Amendment Effective Date?) by and between SOUTH LOOP 1, LLC, a Delaware limited liability company (?Landlord?), and PENUMBRA, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord and Tenant entered into that certain Lease dated Septemb |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 22, 2022 |
Exhibit 10.3 September 11, 2014 Penumbra, Inc. 1351 Harbor Bay Parkway, Suites 100A & 202 Alameda, CA 94502 Attn: Adam Elsesser Dear Adam: This letter when executed shall serve as an agreement modifying that certain lease dated November 28, 2007 and last modified June 23, 2011, by and between Dollinger Harbor Bay Assocaites, as Landlord and Penumbra, Inc., as Tenant, relating to the Premises at 13 |
|
| February 22, 2022 |
Exhibit 10.30 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?First Amendment?) is made and entered into on April 10, 2020 (the ?First Amendment Date?) by and between SOUTH LOOP 1, LLC, a Delaware limited liability company (?Landlord?), and PENUMBRA, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord and Tenant entered into that certain Lease dated September 3, 2019 (the ?L |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 22, 2022 |
Exhibit 10.33 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this ?Fourth Amendment?) is made as of October 15, 2021 (the ?Fourth Amendment Effective Date?), by and between HARBOR BAY CA LLC, a Delaware limited liability company (?Landlord?), and PENUMBRA, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord (as successor-in-interest to South Loop 1, LLC) and Tenant entered into |
|
| February 22, 2022 |
Exhibit 10.19 PENUMBRA, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Penumbra, Inc. 2014 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Stock Option Agreement which includes the Notice of Stock Option Grant (the ?Notice of Grant?), the Terms and Cond |
|
| February 22, 2022 |
Exhibit 10.2 Penumbra, Inc. 1351 Harbor Bay Parkway, Suites 100A & 202 Alameda, CA 94502 Attn: Adam Elsesser Dear Adam: This letter when executed shall serve as an agreement modifying that certain lease dated November 28, 2007 and last modified June 23, 2011, by and between Dollinger Harbor Bay Assocaites, as Landlord and Penumbra, Inc., as Tenant, relating to the Premises at 1351 Harbor Bay Parkw |
|
| February 22, 2022 |
SECOND AMENDMENT TO LEASE AGREEMENT Exhibit 10.8 SECOND AMENDMENT TO LEASE AGREEMENT This Second Amendment to Lease Agreement (this ?Second Amendment?) is made and intended to be effective as of September 1, 2021 (the ?Effective Date?), between HARBOR BAY NLA LLC, a Delaware limited liability company (together with any of its successors or assigns, hereinafter called the ?Landlord?), and PENUMBRA, INC., a Delaware corporation (toget |
|
| February 22, 2022 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results ALAMEDA, CA, February 22, 2022 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. Financial Highlights: ?Revenue of $204.0 million for the fourth quarter of 2021, |
|
| February 22, 2022 |
Exhibit 10.32 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this ?Third Amendment?) is made as of July 29, 2021 (the ?Third Amendment Effective Date?), by and between SOUTH LOOP 1, LLC, a Delaware limited liability company (?Landlord?), and PENUMBRA, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant entered into that certain Lease dated September 3, 2019 (the ?Orig |
|
| February 11, 2022 |
PEN / Penumbra Inc / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
PEN / Penumbra Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Penumbra Inc. Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule |
|
| February 4, 2022 |
PEN / Penumbra Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2022 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 3, 2021 |
Penumbra, Inc. Reports Third Quarter 2021 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2021 Financial Results ALAMEDA, Calif., November 3, 2021 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2021. ?Revenue of $190.1 million in the third quarter of 2021, an increase of 25.8%, or 25.6% in constant currenc |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 7, 2021 |
Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Comm |
|
| September 22, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 17, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (C |
|
| August 9, 2021 |
Penumbra, Inc. Reports Second Quarter 2021 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2021 Financial Results ALAMEDA, Calif., August 9, 2021 /PR Newswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2021. ?Revenue of $184.3 million in the second quarter of 2021, an increase of 75.3%, or 72.7% in constant currency1, |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| June 8, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 4, 2021 |
Penumbra, Inc. Reports First Quarter 2021 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2021 Financial Results ALAMEDA, Calif., May 4, 2021 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2021. ?Revenue of $169.2 million in the first quarter of 2021, an increase of 23.2%, or 21.5% in constant currency1, compa |
|
| May 4, 2021 |
AMENDMENT NO. 1 Dated as of February 22, 2021 CREDIT AGREEMENT Dated as of April 24, 2020 Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 Dated as of February 22, 2021 to CREDIT AGREEMENT Dated as of April 24, 2020 THIS AMENDMENT No. 1 (?Amendment?) is entered into as of February 22, 2021 by and among Penumbra, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?), under |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 23, 2021 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Penumbra, Inc. (?Penumbra,? the ?Company,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, par value $0.001 per share. The following description of our capital stock is |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 23, 2021 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results ALAMEDA, CA, February 23, 2021 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020. Financial Highlights: •Revenue of $166.9 million for the fourth quarter of 2020, |
|
| February 23, 2021 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty. Ltd. Australia Penumbra Neuro Canada Inc. Montr?al (Qu?bec) Canada Penumbra Latin America Distribuidora de Equipamentos e Productos M?dicos LTDA Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Penumbra Inc. Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 11, 2021 |
Penumbra, Inc. Reconciliation of GAAP Revenue to Non-GAAP Revenue1 (in thousands) Penumbra Announces Preliminary Unaudited Revenue for the Fourth Quarter and Full Year 2020 ALAMEDA, Calif. |
|
| January 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2021 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 16, 2020 |
December 16, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. David Burton Ms. Lynn Dicker Ms. Dorrie Yale Ms. Celeste Murphy Re: Penumbra, Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2019 Filed February 26, 2020 File No. 001-37557 Ladies and Gentlemen: This letter is submitted on behalf |
|
| December 15, 2020 |
Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall Exhibit 99.1 Penumbra Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall ALAMEDA, Calif., Dec. 15, 2020 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN) today announced that it is voluntarily recalling all configurations of the Penumbra JET® 7 Reperfusion Catheter with Xtra Flex technology (JET 7 Xtra Flex). Penumbra is recalling JET 7 Xtra Flex because the catheter |
|
| December 15, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 15, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| December 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| December 8, 2020 |
Exhibit 99.1 Penumbra Responds to False Allegations from Short Sellers Seeking to Manipulate Company Stock and Remove Life-saving Medical Devices from the Market ALAMEDA, Calif. – December 8, 2020 - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today responded to recent attacks by short sellers containing inaccurate and misleading information regarding sc |
|
| December 7, 2020 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 7, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| October 28, 2020 |
Penumbra, Inc. Reports Third Quarter 2020 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2020 Financial Results ALAMEDA, Calif., October 28, 2020 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2020. •Revenue of $151.1 million in the third quarter of 2020, an increase of 8.3%, or 7.7% in constant currency1 |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 3, 2020 |
Penumbra, Inc. Reports Second Quarter 2020 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2020 Financial Results ALAMEDA, Calif., August 3, 2020 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2020. •Revenue of $105.1 million in the second quarter of 2020, a decrease of 21.7%, or 21.3% in constant currency1, c |
|
| June 9, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 27, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 1, 2020 |
Exhibit 1.1 PENUMBRA, INC. 753,012 Shares of Common Stock Underwriting Agreement May 27, 2020 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Penumbra, Inc., a |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 28, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-236640 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount To Be Registered Maximum Offering Price per Share Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.001 par value per share 865,963 $166.00 $143,749,858.00 $18,659.00 (1) Calculated in accordance |
|
| May 27, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-236640 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction |
|
| May 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 12, 2020 |
Penumbra Announces Management Transition Exhibit 99.1 Penumbra Announces Management Transition Sri Kosaraju will transition from his role as President to join nonprofit focused on COVID-19 testing; will remain advisor to CEO Adam Elsesser Jason Mills, a seasoned Wall Street Senior Analyst from Canaccord Genuity, joins Penumbra leadership team as Executive Vice President, Strategy ALAMEDA, Calif., May 12, 2020 /PRNewswire/ - Penumbra, Inc |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| May 7, 2020 |
Penumbra, Inc. Reports First Quarter 2020 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2020 Financial Results ALAMEDA, Calif., May 7, 2020 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2020. •Revenue of $137.3 million in the first quarter of 2020, an increase of 6.9%, or 7.6% in constant currency1, over th |
|
| April 24, 2020 |
EXECUTION VERSION CREDIT AGREEMENT dated as of April 24, 2020 among PENUMBRA, INC. |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 6, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commis |
|
| April 6, 2020 |
Exhibit 99.1 Penumbra Provides Update on COVID-19 Response and Impact April 6, 2020 Provides Preliminary Revenue Range for the First Quarter 2020 and Withdraws Prior Annual Revenue Guidance for 2020 Due to COVID-19 Impact ALAMEDA, Calif., April 6, 2020 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today provided an update on the actions it |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 26, 2020 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty. Ltd. Australia Penumbra Neuro Canada Inc. Montréal (Québec) Canada Penumbra Latin America Distribuidora de Equipamentos e Productos Médicos LTDA Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore |
|
| February 26, 2020 |
As filed with the Securities and Exchange Commission on February 26, 2020 Table of Contents As filed with the Securities and Exchange Commission on February 26, 2020 Registration No. |
|
| February 26, 2020 |
630 ROSEVILLE PARKWAY AMENDED AND RESTATED OFFICE LEASE Exhibit 10.25 630 ROSEVILLE PARKWAY AMENDED AND RESTATED OFFICE LEASE This Amended and Restated Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between 8000 FOOTHILLS LLC, a Delaware limited liability company ("Landlord"), and PENUMBRA, INC., a Delaware corporation ("Tenant"). Tenant has been a |
|
| February 26, 2020 |
Exhibit 10.22 October 30, 2019 Ms. Maggie Yuen Dear Maggie, On behalf of Penumbra, Inc. (“Penumbra” or “Company”), I am pleased to offer you employment in the position of Chief Financial Officer, reporting to Sri Kosaraju. This agreement sets out the terms of the Company’s offer of employment and is subject to approval and appointment by the Board of Directors. Please note that this offer is conti |
|
| February 26, 2020 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Penumbra, Inc. (“Penumbra,” the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. The following description of our capital stock is based upon our restat |
|
| February 26, 2020 |
Exhibit 10.19 February 19, 2014 Ms. Johanna Roberts Re: Employment Agreement Dear Johanna: On behalf of Penumbra, Inc. (“Company”), I am pleased to offer you employment in the position of Associate General Counsel, reporting to Robert Evans. This letter sets out the terms of your employment with the Company, which will start on March 10, 2014. You will be paid a base salary of $8,653.85 every two |
|
| February 25, 2020 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results ALAMEDA, CA, February 25, 2020 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019. Financial Highlights: •Revenue of $145.3 million for the fourth quarter of 2019, |
|
| February 25, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2020 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 12, 2020 |
PEN / Penumbra, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Penumbra Inc Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| December 9, 2019 |
PEN / Penumbra, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) November 29, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| November 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 25, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| November 25, 2019 |
Exhibit 99.1 Maggie Yuen Appointed Chief Financial Officer Of Penumbra Following the Promotion of Sri Kosaraju to President in August, Maggie Yuen will assume responsibilities as chief financial officer and Lambert Shiu will become chief accounting officer. ALAMEDA, Calif., November 25, 2019 (PRNewswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, tod |
|
| November 7, 2019 |
Penumbra, Inc. Reports Third Quarter 2019 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2019 Financial Results ALAMEDA, Calif., November 7, 2019 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2019. •Revenue of $139.5 million in the third quarter of 2019, an increase of 24.8%, or 25.5% in constant currenc |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 7, 2019 |
SUMMARY OF BASIC LEASE INFORMATION LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between SOUTH LOOP 1, LLC, a Delaware limited liability company (“Landlord”), and PENUMBRA, INC. |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| September 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 3, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| August 29, 2019 |
SRI KOSARAJU PROMOTED TO PRESIDENT AND CFO OF PENUMBRA Kosaraju will add duties to his current responsibilities as chief financial officer ALAMEDA, Calif. |
|
| August 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 6, 2019 |
Penumbra, Inc. Reports Second Quarter 2019 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2019 Financial Results ALAMEDA, Calif., August 6, 2019 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2019. •Revenue of $134.2 million in the second quarter of 2019, an increase of 22.4%, or 23.8% in constant currency1, |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| June 10, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 5, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 10, 2019 |
PEN / Penumbra, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) May 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| May 30, 2019 |
PEN / Penumbra, Inc. SD - - SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 7, 2019 |
Penumbra, Inc. Reports First Quarter 2019 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2019 Financial Results ALAMEDA, Calif., May 7, 2019 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2019. •Revenue of $128.4 million in the first quarter of 2019, an increase of 25.1%, or 27.2% in constant currency1, over |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| April 26, 2019 |
PEN / Penumbra, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 12, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| February 26, 2019 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty. Ltd. Australia Penumbra Neuro Canada Inc. Montréal (Québec) Canada Penumbra Latin America Distribuidora de Equipamentos e Productos Médicos LTDA Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore |
|
| February 26, 2019 |
PEN / Penumbra, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 26, 2019 |
Exhibit 10.14 PENUMBRA, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Penumbra, Inc. Amended and Restated 2014 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restricted St |
|
| February 26, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Co |
|
| February 26, 2019 |
Exhibit 10.13 PENUMBRA, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Penumbra, Inc. Amended and Restated 2014 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restricted St |
|
| February 26, 2019 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results ALAMEDA, CA, February 26, 2019 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018. Financial Highlights: • Revenue of $120.8 million for the fourth quarter of 2018, |
|
| February 12, 2019 |
PEN / Penumbra, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Penumbra, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2019 |
PEN / Penumbra, Inc. / VANGUARD GROUP INC Passive Investment penumbrainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Penumbra Inc Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designat |
|
| January 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 January 17, 2019 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| January 18, 2019 |
Penumbra, Inc. Appoints Janet Leeds and Surbhi Sarna to its Board of Directors Exhibit 99.1 Penumbra, Inc. Appoints Janet Leeds and Surbhi Sarna to its Board of Directors ALAMEDA, Calif., January 18, 2019 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN) today announced that two new Board members were appointed to its Board of Directors (the “Board”) on January 17, 2019. Ms. Janet Leeds was appointed to the Board as a Class I director, effective immediately, and Ms. Surbhi Sarna was |
|
| November 5, 2018 |
Penumbra, Inc. Reports Third Quarter 2018 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2018 Financial Results ALAMEDA, Calif., November 5, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2018. • Revenue of $111.8 million in the third quarter of 2018, an increase of 33.2% over the third quarter of 20 |
|
| November 5, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Com |
|
| November 5, 2018 |
PEN / Penumbra, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penum |
|
| September 4, 2018 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 31, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 7, 2018 |
PEN / Penumbra, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 7, 2018 |
Penumbra, Inc. Reports Second Quarter 2018 Financial Results Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2018 Financial Results ALAMEDA, Calif., August 7, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2018. • Revenue of $109.6 million in the second quarter of 2018, an increase of 36.0%, or 33.8% in constant currency1, |
|
| July 2, 2018 |
PEN / Penumbra, Inc. 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| June 21, 2018 |
June 21, 2018 Kevin J. Kuhar Accounting Branch Chief Office of Electronics and Machinery Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Penumbra, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed February 27, 2018 Form 10-Q for the Quarterly Period Ended March 31, 2018 Filed May 8, 2018 File No. 001-3755 |
|
| June 8, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 6, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 31, 2018 |
PEN / Penumbra, Inc. PEN FORM SD YEAR ENDED 31DEC2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT PENUMBRA, INC. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) One Penumbra Place, Alameda, California 94502 (Address of principal executive off |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 8, 2018 |
Penumbra, Inc. Reports First Quarter 2018 Financial Results Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2018 Financial Results ALAMEDA, Calif., May 8, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2018. • Revenue of $102.7 million in the first quarter of 2018, an increase of 40.3%, or 36.2% in constant currency1, over |
|
| May 8, 2018 |
PEN / Penumbra, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| April 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 28, 2018 |
As filed with the Securities and Exchange Commission on March 28, 2018 Registration No. |
|
| February 27, 2018 |
Penumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results Exhibit Exhibit 99.1 Penumbra, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results ALAMEDA, CA, February 27, 2018 (PR Newswire) - Penumbra, Inc. (NYSE: PEN) , a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2017 . Financial Highlights: ? Revenue of $96.1 million for the fourth quarter |
|
| February 27, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2018 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organiza |
|
| February 27, 2018 |
Exhibit 21.1 SUBSIDIARIES OF PENUMBRA, INC. Name of Subsidiary Jurisdiction of Organization Penumbra Europe GmbH Germany Penumbra Neuro Australia Pty. Ltd. Australia Penumbra Neuro Canada Inc. Montréal (Québec) Canada Penumbra Latin America Distribuidora de Equipamentos e Productos Médicos LTDA Brazil Crossmed S.p.A. Italy Penumbra Interventional Therapies UK Ltd. United Kingdom Penumbra Singapore |
|
| February 27, 2018 |
PEN / Penumbra, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37557 Penumbra, Inc. |
|
| February 15, 2018 |
PEN / Penumbra, Inc. / Penumbra Inc - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240. 13d-2 (Amendment No. 2)* Penumbra, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 70975L107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires F |
|
| February 9, 2018 |
PEN / Penumbra, Inc. / VANGUARD GROUP INC Passive Investment penumbrainc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Penumbra Inc Title of Class of Securities: Common Stock CUSIP Number: 70975L107 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designat |
|
| November 7, 2017 |
Penumbra, Inc. Reports Third Quarter 2017 Financial Results Exhibit Exhibit 99.1 Penumbra, Inc. Reports Third Quarter 2017 Financial Results ALAMEDA, Calif., November 7, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN) , a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, 2017 . ? Revenue of $83.9 million in the third quarter of 2017 , an increase of 24.9% , or 24.1% in |
|
| November 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organizat |
|
| November 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37 |
|
| September 26, 2017 |
Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporat |
|
| September 19, 2017 |
Financial Statements and Exhibits Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 3, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organizatio |
|
| September 19, 2017 |
PENUMBRA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit PENUMBRA, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION References herein to ?we,? ?us,? ?our,? ?Company,? and ?Penumbra,? refer to Penumbra, Inc. and its consolidated subsidiaries unless the context specifically states otherwise. On July 3, 2017, Penumbra acquired all of the outstanding shares of Crossmed S.p.A., a joint stock company organized and existing under the l |
|
| September 19, 2017 |
Exhibit FINANCIAL STATEMENTS Crossmed S.p.A. Year Ended December 31, 2016 With Independent Auditors? Report Crossmed S.p.A. FINANCIAL STATEMENTS TABLE OF CONTENTS Page Independent Auditors? Report 1 Audited Financial Statements Balance Sheet 2 Statement of Operations 3 Statement of Cash Flows 4 Statement of Stockholders? Equity 5 Notes to Financial Statements 6 INDEPENDENT AUDITORS' REPORT To the |
|
| August 8, 2017 |
Penumbra, Inc. Reports Second Quarter 2017 Financial Results Exhibit Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2017 Financial Results ALAMEDA, Calif., August 8, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN) , a global healthcare company focused on interventional therapies, today reported financial results for the second quarter ended June 30, 2017 . • Revenue of $80.6 million in the second quarter of 2017 , an increase of 23.8% , or 24.6% in cons |
|
| August 8, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organizatio |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 Penumbra, |
|
| July 10, 2017 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 3, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) |
|
| June 13, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) |
|
| June 9, 2017 |
Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 June 7, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) |
|
| May 9, 2017 |
Penumbra 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37557 |
|
| May 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2017 Date of Report (Date of earliest event reported) Penumbra, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37557 05-0605598 (State or other jurisdiction of incorporation or organization) |
|
| May 9, 2017 |
Penumbra, Inc. Reports First Quarter 2017 Financial Results Exhibit Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2017 Financial Results ALAMEDA, Calif., May 9, 2017 (PR Newswire) - Penumbra, Inc. (NYSE: PEN) , a global healthcare company focused on interventional therapies, today reported financial results for the first quarter ended March 31, 2017 . ? Revenue of $73.2 million in the first quarter of 2017 , an increase of 26.4% , or 27.0% in constant |
